Meltwind Advisory

Inotec AMD is a medical device company focused on advancing wound care through its innovative product, Natrox. Natrox is a battery-operated device that generates a continuous flow of pure humidified oxygen from ambient air and directs it to a specially-designed Oxygen Delivery System. This system is engineered to deliver oxygen directly to the wound bed while allowing normal exudate drainage, thereby facilitating the healing of chronic wounds, including diabetic foot ulcers and pressure ulcers. Additionally, the company employs artificial intelligence to analyze wound images and monitor healing progression, allowing healthcare providers to track treatment efficacy and communicate with patients in real-time. Through these technologies, Inotec AMD aims to enhance the quality of life for individuals suffering from chronic wounds.

Shift Bioscience employs simulation-guided techniques to identify safer gene factors for cellular rejuvenation, aiming to develop a drug family that treats multiple age-related diseases. Its high-throughput aging biomarker enables accurate cell simulations, with the goal of making full health in old age accessible via prescription.

NanoSyrinx is a biotechnology company focused on developing a novel biologics drug delivery platform that targets therapeutic proteins and peptides to the cytosol of cells. Through synthetic biology, the company seeks to transport payloads directly into cell interiors, aiming to improve the efficacy, safety, and cost-effectiveness of treatments. The platform is designed to serve the biopharmaceutical sector by enabling targeted delivery of biologics to intracellular targets, with potential to enhance treatment outcomes across multiple indications.

Infinitopes is a cancer research organization focused on immunotherapy to prevent metastasis and improve survival. The company develops a platform that combines efficient vector delivery with tumor target identification technologies to enable early-stage clinical trials and therapies designed to stop cancer before it spreads. Its cancer vaccine platform aims to prevent metastases by identifying tumor-specific peptides with high accuracy and delivering them through a durable viral vector, supporting post-surgical relapse prevention for esophageal cancer patients and advancing earlier, smarter immunotherapy. By integrating immune system strengthening and targeted peptide delivery, Infinitopes seeks to create treatments that intervene at early stages to reduce relapse and improve outcomes.

Qureight is a healthcare technology company specializing in imaging analytics. It employs artificial intelligence and advanced processing tools to derive insights from large clinical datasets, focusing on respiratory diseases like Idiopathic Pulmonary Fibrosis (IPF) and lung cancer.

Tagomics specializes in epigenetic biomarker discovery using epigenetic chemical modifications. These modifications provide an additional layer of information to DNA, making them more dynamic and sensitive to lifestyle factors, environment, and disease. This enables early detection of common cancers like colorectal cancer.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Kuano Ltd is a London-based company that specializes in providing quantum and artificial intelligence solutions for molecular design, particularly in the fields of drug discovery and development. Founded in 2020, Kuano has developed a unique discovery platform that integrates quantum simulation with AI-led chemistry, enabling the design of effective inhibitors by analyzing the mechanisms of target enzymes. This innovative approach allows for faster and more efficient development of drug candidates, enhancing the quality of new pharmaceuticals while simultaneously reducing the time required for discovery. The company's solutions are applicable across various sectors, including pharmaceuticals, crop protection, and industrial chemistry.

NK:IO is a biotechnology company focused on developing natural killer cell-mediated immunotherapies for cancer. The company develops both cell therapies and small molecule therapeutics designed to target cancer and enhance the tumor-killing activity of natural killer cells.

Scarlet Therapeutics is focused on creating innovative red blood cell-based therapeutics through its proprietary platform for generating therapeutic red blood cells (tRBCs). These tRBCs are designed to carry additional proteins that deliver therapeutic benefits, allowing for broad application across various medical conditions. The company aims to address a range of diseases, including hyperammonemia, hyperoxaluria, metabolic disorders, cancer, and autoimmune diseases. By utilizing cell lines for therapeutic generation rather than relying on donated stem cells, Scarlet Therapeutics seeks to enhance the efficacy of treatments in the healthcare sector, potentially transforming the approach to disease management.

Founded in 2016, Five Alarm Bio is a biotechnology company based in Cambridge, UK. It focuses on drug discovery to develop anti-aging therapies using a small molecule approach, aiming to enhance the body's defenses against aging-related damage and diseases.

Oxford Drug Design is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. The company employs advanced methodologies in computer-aided drug discovery, encompassing the entire process from target identification to preclinical studies and formulation. Its multidisciplinary research team integrates breakthroughs in computational chemistry, cheminformatics, mathematics, and cloud computing to enhance drug discovery efforts. The company's flagship platform, DrugFinder, represents a next-generation approach to identifying and developing new antibiotics, particularly targeting challenging diseases with significant unmet medical needs. By leveraging these technologies, Oxford Drug Design aims to provide healthcare professionals with effective treatment options for patients suffering from antibiotic-resistant bacterial infections.

52 North Health develops an AI-powered medical device for determining neutropenic sepsis risk in chemotherapy patients. Its portable finger-prick blood test measures neutrophil count and C-Reactive Protein (CRP) levels at home, enabling early detection and improved management of this fatal side effect.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Qureight is a healthcare technology company specializing in imaging analytics. It employs artificial intelligence and advanced processing tools to derive insights from large clinical datasets, focusing on respiratory diseases like Idiopathic Pulmonary Fibrosis (IPF) and lung cancer.

Closed Loop Medicine designs and develops healthcare technology software that optimizes drug dosing on an individual level through integrated digital therapies. The company focuses on improving patient outcomes for chronic diseases, with products in development for hypertension and insomnia.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

Sanome develops clinical decision support software that creates a real-time digital twin of an individual's health. The platform integrates with electronic health records to analyze clinical data and deliver explainable, regulated AI-enabled tools embedded in clinical workflows, helping healthcare providers identify emerging risks earlier and make faster, more accurate decisions as part of a proactive, preventive model of care. By combining artificial intelligence with diverse data streams, including at-home biomarker tests, the system translates information into actionable insights to support early detection and improved patient outcomes.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Cytoseek Limited is a biotechnology company based in Bristol, United Kingdom, that specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Founded in 2017 as a spinout from the University of Bristol, Cytoseek focuses on cell membrane augmentation technology, which enhances the functionality of cell therapies by enabling tissue-specific targeting and improving cell survivability. The company is currently conducting proof of principle studies to validate the efficacy of its technologies and is actively seeking partnerships with other cell therapy organizations to advance its products towards clinical application, with the overarching goal of improving human health.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Kalium Health Ltd is a medical technology company based in Cambridge, United Kingdom, that specializes in designing and manufacturing innovative tests for blood potassium concentration. Founded in 2018 and previously known as Kalium Diagnostics Ltd, the company focuses on patient-centric approaches to manage kidney disease, which significantly impacts healthcare costs. Kalium Health is developing a user-friendly finger-prick blood test that allows patients to monitor their potassium levels conveniently and affordably, addressing a critical risk associated with kidney disease. This technology aims to provide real-time, clinically actionable health insights into cardiorenal diseases, thereby transforming the standard of care for millions of patients. With a clear regulatory pathway and a targeted go-to-market strategy, Kalium Health is positioned to make a significant impact in the field of kidney care.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.